A new study reveals that the protein L1CAM (CD171) plays a key role in driving the aggressive spread of Glioblastoma (GBM) cells into healthy brain tissue. Glioblastoma is notoriously difficult to treat because its cells migrate away from the main tumor, leading to relapse. Researchers used patient-derived neurosphere cells grown in serum-free conditions to better replicate the behavior of actual human tumors.
The study found that L1CAM acts as a “molecular clutch,” helping GBM cells move through the brain’s laminin-rich environment. On the cell surface, L1CAM binds to laminin, while inside the cell it connects to F-actin, the internal “conveyor belt.” This connection converts internal cellular energy into forward movement. L1CAM-high cells migrated faster and further on laminin compared with other surfaces, while treating them with anti-L1CAM antibodies effectively “disengaged the clutch” and reduced migration. In mouse models, overexpression of L1CAM caused tumors to spread wider and deeper into brain tissue, even without increasing cell proliferation.
Clinical data from TCGA show that patients with high L1CAM expression have significantly shorter overall survival. Because L1CAM drives migration through its extracellular domain, it is accessible to antibody-based therapies. Blocking L1CAM could help contain tumor spread, potentially improving the effectiveness of surgery and radiation. This research identifies L1CAM as both a prognostic marker and a promising therapeutic target for one of the most challenging brain cancers.